Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome

Key Points

• Current therapeutic options can improve outcomes for patients with metabolic dysfunction-associated steatotic liver disease.
• Diagnosis remains complex, often requiring a combination of clinical and imaging assessments for metabolic syndrome.
• Therapies targeting comorbid conditions may positively influence the progression of metabolic dysfunction-associated steatotic liver disease.
• Understanding the pathogenesis helps refine prognostic approaches and optimize management strategies for affected patients.